OPCML at 11q25 is epigenetically inactivated and has tumor- suppressor function in epithelial ovarian cancer

Nature Genetics

Volumn 34, Issue 3, 2003, Pages 337-343

  Sellar, Grant C ^a   Watt, Karen P ^a   Rabiasz, Genevieve J ^a   Stronach, Euan A ^a   Li, Li ^a,e   Miller, Eric P ^a   Massie, Charles E ^a   Miller, Jayne ^a   Contreras Moreira, Bruno ^b   Scott, Diane ^a   Brown, Iain ^c   Williams, Alastair R ^d   Bates, Paul A ^b   Smyth, John F ^a   Gabra, Hani ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; GLYCOSYLPHOSPHATIDYLINOSITOL; IMMUNOGLOBULIN;

ALLELE; ARTICLE; CANCER INHIBITION; CHROMOSOME 11Q; CONTROLLED STUDY; CPG ISLAND; CPG ISLAND METHYLATION; EPIGENETIC INACTIVATION; GENE; GENE INACTIVATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; METASTASIS; MISSENSE MUTATION; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; ONCOGENE; OPCML GENE; OVARY CANCER; PERITONEAL CAVITY; PERITONEUM METASTASIS; PRIORITY JOURNAL; SOMATIC CELL GENETICS; TUMOR SUPPRESSOR GENE;

ANIMALS; AZACITIDINE; BREAST NEOPLASMS; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CHROMOSOMES, HUMAN, PAIR 11; CPG ISLANDS; DNA; DNA METHYLATION; ENZYME INHIBITORS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MICE; MICE, NUDE; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; NERVE TISSUE PROTEINS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0038081144     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng1183     Document Type: Article

References (30)

1. Chi, D.S. et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol. Oncol. 82, 532-537 (2001).
2. Hoskins, W.J. Prospective on ovarian cancer: why prevent? J. Cell. Biochem. Suppl. 23, 189-199 (1995).
3. Auersperg, N., Wong, A.S., Choi, K.C., Kang, S.K. & Leung, P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22, 255-288 (2001).
4. Thiagalingam, S. et al. Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Curr. Opin. Oncol. 14, 65-72 (2002).
5. Davis, M., Hitchcock, A., Foulkes, W.D. & Campbell, I.G. Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res. 56, 741-744 (1996).
6. Gabra, H. et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res. 56, 950-954 (1996).
7. Gabra, H. et al. Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br. J. Cancer 72, 367-375 (1995).
8. Foulkes, W.D., Campbell, I.G., Stamp, G.W. & Trowsdale, J. Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br. J. Cancer 67, 268-273 (1993).
9. Launonen, V. et al. Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions. Gynecol. Oncol. 71, 299-304 (1998).
10. Jones, P.A. & Laird, P.W. Cancer epigenetics comes of age. Nat. Genet. 21, 163-167 (1999).
11. Shark, K.B. & Lee, N.M. Cloning, sequencing and localization to chromosome 11 of a cDNA encoding a human opioid-binding cell adhesion molecule (OBCAM). Gene 155, 213-217 (1995).
12. Harpaz, Y. & Chothia, C. Many of the immunoglobulin superfamily domains in cell adhesion molecules and surface receptors belong to a new structural set which is close to that containing variable domains. J. Mol. Biol. 238, 528-539 (1994).
13. Wilson, D.J., Kim, D.S., Clarke, G.A., Marshall-Clarke, S. & Moss, D.J. A family of glycoproteins (GP55), which inhibit neurite outgrowth, are members of the Ig superfamily and are related to OBCAM, neurotrimin, LAMP and CEPU-1. J. Cell Sci. 109, 3129-3138 (1996).
14. Gil, O.D., Zanazzi, G., Struyk, A.F. & Salzer, J.L. Neurotrimin mediates bifunctional effects on neurite outgrowth via homophilic and heterophilic interactions. J. Neurosci. 18, 9312-9325 (1998).
15. Funatsu, N. et al. Characterization of a novel rat brain glycosylphosphatidylinositol-anchored protein (Kilon), a member of the IgLON cell adhesion molecule family. J. Biol. Chem. 274, 8224-8230 (1999).
16. Hachisuka, A., Nakajima, O., Yamazaki, T. & Sawada, J. Developmental expression of opioid-binding cell adhesion molecule (OBCAM) in rat brain. Brain Res. Dev. Brain Res. 122, 183-191 (2000).
17. Lodge, A.P., Howard, M.R., McNamee, C.J. & Moss, D.J. Co-localisation, heterophilic interactions and regulated expression of IgLON family proteins in the chick nervous system. Brain Res. Mol. Brain Res. 82, 84-94 (2000).
18. Miyata, S. et al. Expression of the IgLON cell adhesion molecules Kilon and OBCAM in hypothalamic magnocellular neurons. J. Comp. Neurol. 424, 74-85 (2000).
19. Rai, S.K. et al. Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation. Proc. Natl. Acad. Sci. USA 98, 4443-4448 (2001).
20. Ji, L. et al. Expression of several genes in the human chromosome 3p21,3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res. 62, 2715-2720 (2002).
21. Haber, D. & Hadow, E. Tumour-suppressor genes: evolving definitions in the genomic age. Nat. Genet. 16, 320-322 (1997).
22. Ponder, B.A. Cancer genetics. Nature 411, 336-341 (2001).
23. Balmain, A. Cancer: new-age tumour suppressors. Nature 417, 235-237 (2002).
24. Li, Q.L. et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109, 113-124 (2002).
25. Sellar, G.C. et al. BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression. Cancer Res. 61, 6977-6981 (2001).
26. Axton, R.A. et al. Combined SSCP/heteroduplex analysis in the screening for PAX6 mutations. Mol. Cell. Probes 11, 287-292 (1997).
27. Thompson, J.D., Higgins, D.G. & Gibson, T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22, 4673-4680 (1994).
28. Altschul, S.F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402 (1997).
29. Freigang, J. et al. The crystal structure of the ligand binding module of axonin-1/TAG-1 suggests a zipper mechanism for neural cell adhesion. Cell 101, 425-433 (2000).
30. Bates, P.A., Kelley, L.A., MacCallum, R.M. & Sternberg, M.J. Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins 45 Suppl. 5, 39-46 (2001).